CAN CABENUVA
KEEP ME UNDETECTABLE?
At Week 48 in all studies:
- 9 out of 10 people remained undetectable, whether they were on daily HIV pills or CABENUVA
- Less than 2% of people did not remain undetectable (primary endpoint)
*Undetectable means the amount of HIV in the blood is below the level that can be measured by a lab test. Results may vary.
†Daily pill regimens contained dolutegravir and 2 nucleoside reverse transcriptase inhibitors (NRTIs) or 2 NRTIs plus a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).
Results were consistent:
- After 96 weeks
- With both once-monthly and every-other-month regimens
- Whether or not people took starter pills before beginning injections
- Across a diverse range of ages, races and genders, including transgender people
CABENUVA was also tested in people 12 years and older who weigh at least 77 lbs (35 kg).
SIDE
EFFECTS
Injection-site reactions were reported less often the longer people were on treatment.§
Aside from injection-site reactions, the most common side effects to occur in less than 9% of people were:
- Fever
- Tiredness
- Headache
- Muscle or bone pain
- Nausea
- Sleep problems
- Dizziness
- Rash
Less than 4% of people on CABENUVA stopped treatment due to any side effect.||
These are not the only side effects of CABENUVA. For more information, see the Risks & Side Effects page. Always tell your doctor if you experience any side effects.
Results may vary.
‡Injection-site reactions include pain, tenderness, hardened mass or lump, swelling, redness, itching, bruising and warmth at the injection site.
§The true rate of injection-site reactions over time may be underestimated, as symptoms that occurred may not have been reported during the study.
||4% of people on once-monthly CABENUVA; 2% of people on every-other-month CABENUVA.
DID PEOPLE
PREFER LONG-ACTING TREATMENT?
PMUS-CBRWCNT240049